Tivicay / Tivicay PD Medical Information - Our HIV Medications

Prescribing Information

Patient Information

Medical Information Documents
Data in Pediatrics

Use of Tivicay in Pediatric Patients

Tivicay PD (MI letter)

Tivicay PD Overview (Infographic)

Resistance Data

Treatment-Emergent Resistance in Treatment-Naïve Patients

Safety Data

Occurrence of Neural Tube Defects (MI letter)

Maternal and Infant Outcomes During Pregnancy

Psychiatric Events

Effect on Renal Function

Weight Gain

Weight Gain Overview

Clinical Trial Data (Infographic)

Drug-Drug Interactions and Absorption

Metabolism of and Drug Interactions with Tivicay

Use with Tecovirimat

Administration via NG Tube Feeding

Storage and Stability

Splitting/Crushing

Expiration, Repackaging, and Storage Conditions (MI letter)

Expiration, Partial Dispensing, Unit-Dose, and Temp Stability (Infographic)
On Demand Medical Videos
Congress Data

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Clinical Trials Data

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

The Use of Tivicay plus Epivir for Treatment-Naïve Adults with HIV-1
GEMINI-1 and GEMINI-2 Studies
Michael Aboud, VP, Global Medical Lead, Dolutegravir

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Dosing

Tivicay PD: An Option for Children Living with HIV

Ana M. Puga, MD, Regional Medical Director

Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director

Pharmacokinetics

Tivicay PD: An Option for Children Living with HIV

Ana M. Puga, MD, Regional Medical Director

Tivicay PD: An Option for Children Living with HIV
Ana M. Puga, MD, Regional Medical Director

Safety

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar
Andrew Zolopa, MD, VP, Head, North America Medical Affairs

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Antiretroviral Therapy and Weight Gain

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Antiretroviral Therapy and Weight Gain
Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Data in Pediatrics

Tivicay PD (Video)

Tivicay PD (Video)

Weight Gain

Weight Gain (Video)

Weight Gain (Video)

Metabolic Health (Video)

Metabolic Health (Video)

Connect With Us

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Yes